CalciMedica IncNASDAQ:CALC
- LAST PRICE5.4900
- TODAY'S CHANGE (%)0.9000 (19.6078%)
- Bid / Lots5.3200/ 5
- Ask / Lots5.8500/ 3
- Open / Previous Close4.5400 / 4.5900
- Day Range
- 52 Week Range
- Volume76,715
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CALC |
|---|---|---|
| 09:32 ET | 1932 | 4.12 |
| 09:41 ET | 432 | 4.33 |
| 09:50 ET | 684 | 4.37 |
| 09:52 ET | 640 | 4.5399 |
| 10:14 ET | 1000 | 4.54 |
| 10:24 ET | 3592 | 4.54 |
| 10:26 ET | 4219 | 4.55 |
| 10:30 ET | 130 | 4.35 |
| 10:32 ET | 100 | 4.54 |
| 11:15 ET | 2042 | 4.95 |
| 11:18 ET | 815 | 4.95 |
| 12:38 ET | 287 | 4.84 |
| 01:39 ET | 144 | 4.6 |
| 01:44 ET | 100 | 4.59 |
| 02:09 ET | 1770 | 4.79 |
| 02:11 ET | 1844 | 5.02 |
| 02:15 ET | 2976 | 5.204 |
| 02:18 ET | 3702 | 5.2 |
| 02:20 ET | 400 | 5.3147 |
| 02:22 ET | 300 | 5.4 |
| 02:24 ET | 1700 | 5.22 |
| 02:26 ET | 576 | 5.365 |
| 02:29 ET | 534 | 5.365 |
| 02:31 ET | 100 | 5.22 |
| 02:47 ET | 1396 | 5.5499 |
| 02:49 ET | 400 | 5.38 |
| 02:51 ET | 711 | 5.69 |
| 02:54 ET | 104 | 5.6 |
| 02:56 ET | 400 | 5.6 |
| 02:58 ET | 4658 | 5.5325 |
| 03:00 ET | 2300 | 5.5663 |
| 03:05 ET | 300 | 5.55 |
| 03:07 ET | 3482 | 5.6 |
| 03:09 ET | 2671 | 5.7 |
| 03:12 ET | 300 | 5.75 |
| 03:14 ET | 1330 | 5.75 |
| 03:16 ET | 6194 | 5.74 |
| 03:18 ET | 600 | 5.8 |
| 03:23 ET | 800 | 5.56 |
| 03:27 ET | 200 | 5.7 |
| 03:30 ET | 100 | 5.7 |
| 03:32 ET | 2071 | 5.6 |
| 03:34 ET | 1591 | 5.7 |
| 03:36 ET | 200 | 5.55 |
| 03:38 ET | 3310 | 5.39 |
| 03:39 ET | 200 | 5.43 |
| 03:41 ET | 1100 | 5.35 |
| 03:45 ET | 200 | 5.45 |
| 03:50 ET | 127 | 5.5 |
| 03:54 ET | 500 | 5.4896 |
| 03:56 ET | 400 | 5.45 |
| 03:57 ET | 1982 | 5.48 |
| 03:59 ET | 100 | 5.49 |
Today
Apr 1, 2024
DJ CalciMedica Is Maintained at Outperform by Oppenheimer, from 9:26AM ET on Monday Apr 01, 2024 by Dow Jones
9:26AM ET on Monday Apr 01, 2024 by Dow JonesDJ CalciMedica Price Target Maintained With a $20.00/Share by HC Wainwright & Co., from 6:42AM ET on Monday Apr 01, 2024 by Dow Jones
6:42AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 28, 2024
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates, from 7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
7:00AM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates, from 7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
7:00AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CalciMedica Inc | 49.3M | -0.2x | --- |
Quince Therapeutics Inc | 48.0M | -1.3x | --- |
Maia Biotechnology Inc | 50.6M | -1.8x | --- |
Immuneering Corp | 47.7M | -0.8x | --- |
Ocean Biomedical Inc | 51.3M | -1.0x | --- |
Checkpoint Therapeutics Inc | 51.2M | -0.5x | --- |
Company Information
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
Contact Information
- Headquarters
- 505 Coast Boulevard South, Suite 307LA JOLLA, CA, United States 92037
- Phone
- 858-952-5500
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Robert Wilson
- President, Chief Operating Officer
- Michael Dunn
- Chief Executive Officer, Director
- A. Rachel Leheny
- Interim Chief Financial Officer
- Daniel Geffken
- Chief Scientific Officer
- Kenneth Stauderman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $49.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-26.09 |
Book Value | $1.43 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
